The effect of thiazolidinediones on plasma adiponectin levels in normal, obese, and type 2 diabetic subjects

Diabetes

Volumn 51, Issue 10, 2002, Pages 2968-2974

  Yu, Joseph G ^a,b,c   Javorschi, Sandrine ^d   Hevener, Andrea L ^a,b,c   Kruszynska, Yolanta T ^a,b,c   Norman, Rodney A ^d   Sinha, Madhur ^e   Olefsky, Jerrold M ^a,b,c,f  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

^c Whittier Institute for Diabetes   (United States)

^d SET Corporation   (United States)

^e Linco Research Inc   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ADIPONECTIN; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PLASMINOGEN ACTIVATOR INHIBITOR 1; RESISTIN; THIAZOLIDINE DERIVATIVE; TRIACYLGLYCEROL; TROGLITAZONE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADIPOCYTE; ADIPOSE TISSUE; ADULT; ARTICLE; BODY WEIGHT; CLINICAL ARTICLE; CONTROLLED STUDY; FATTY ACID OXIDATION; FEMALE; GLUCOSE CLAMP TECHNIQUE; HUMAN; INSULIN BLOOD LEVEL; INSULIN SENSITIVITY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PRIORITY JOURNAL; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 0036789137     PISSN: 00121797     EISSN: None     Source Type: Journal    
DOI: 10.2337/diabetes.51.10.2968     Document Type: Article

References (43)

1. Mohamed-Ali V, Pinkney JH, Coppack SW: Adipose tissue as an endocrine and paracrine organ. Int J Obes Relat Metab Disord 22:1145-1158, 1998
2. Hotamisligil GS: The role of TNF-α and TNF receptors in obesity and insulin resistance. J Intern Med 245:621-625, 1999
3. White RT, Damm D, Hancock N, Rosen BS, Lowell BB, Usher P, Flier JS, Spiegelman BM: Human adipsin is identical to complement factor D and is expressed at high levels in adipose tissue. J Biol Chem 267:9210-9213, 1992
4. Shimomura I, Funahashi T, Takahashi M, Maeda K, Kotani K, Nakamura T, Yamashita S, Miura M, Fukuda Y, Takemura K, Tokunaga K, Matsuzawa Y: Enhanced expression of PAI-1 in visceral fat: possible contributor to vascular disease in obesity. Nature Med 2:800-803, 1996
5. Friedman JM, Halaas JL: Leptin and the regulation of body weight in mammals. Nature 395:763-770, 1998
6. Shimomura I, Hammer R, Ikemoto S, Brown MS, Goldstein JL: Leptin reverses insulin resistance and diabetes mellitus in mice with congenital lipoatrophy. Nature 401:73-76, 1999
7. Steppan CM, Bailey ST, Bhat S, Brown EJ, Banerjee RR, Wright CM, Patel HR, Ahima RS, Lazar MA: The hormone resistin links obesity to diabetes. Nature 409:307-312, 2001
8. Scherer PE, Williams S, Fogliano M, Baldini G, Lodish HF: A novel serum protein similar to C1q, produced exclusively in adipocytes. J Biol Chem 270:26746-26749, 1995
9. Hu E, Liang P, Spiegelman BM: AdipoQ is a novel adipose-specific gene dysregulated in obesity. J Biol Chem 271:10697-10703, 1996
10. Henry RR: Thiazolidinediones. Endocrinol Metab Clin North Am 26:553-573, 1997
11. Nagy L, Tontonoz P, Alvarez JGA, Chen H, Evans RM: Oxidized LDL regulates macrophage gene expression through ligand activation of PPARγ. Cell 93:229-240, 1998
12. Ricote M, Li AC, Willson TM, Kelly CJ, Glass CK: The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature 391:79-82, 1998
13. Moore KJ, Rosen ED, Fitzgerald ML, Randow F, Andersson LP, Altshuler D, Milstone DM, Mortensen RM, Spiegelman BM, Freeman MW: The role of PPARγ in macrophage differentiation and cholesterol uptake. Nature Med 7:41-47, 2001
14. Law RE, Goetze S, Xi XP, Jackson S, Kawano Y, Demer L, Fishbein MC, Meehan WP, Hsueh WA: Expression and function of PPARγ in rat and human vascular smooth muscle cells. Circulation 101:1311-1318, 2000
15. Clark RB, Bishop-Bailey D, Estrada-Hernandez T, Hla T, Puddington L, Padula SJ: The nuclear receptor PPARγ and immunoregulation: PPARγ mediates inhibition of helper T-cell responses. J Immunol 164:1364-1371, 2000
16. Rosen E, Sarraf P, Troy AE, Bradwin G, Moore K, Milstone DS, Spigelman BM, Mortensen M: PPARγ is required for the differentiation of adipose tissue in vivo and in vitro. Mol Cell 4:611-617, 1999
17. Tontonoz P, Hu E, Spigelman BM: Stimulation of adipogenesis in fibroblasts by PPARγ2, a lipid-activated transcription factor. Cell 79:1147-1156, 1994
18. Olefsky JM: Treatment of insulin resistance with peroxisome proliferator-activated receptor γ agonists. J Clin Invest 106:467-472, 2000
19. Savage DB, Sewter CP, Klenk ES, Segal DG, Vidal-Puig A, Considine RV, O'Rahilly SO: Resistin/Fizz3 expression in relation to obesity and peroxisome proliferator-activated receptor-γ action in humans. Diabetes 50: 2199-2202, 2001
20. Way JM, Gorgun CZ, Tong Q, Uysal KT, Brown KK, Harrington WW, Oliver WR, Willson TM, Kliewer SA, Hotamisligil GS: Adipose tissue resistin expression is severely suppressed in obesity and stimulated by peroxisome proliferator-activated receptor gamma agonists. J Biol Chem 276:25651-25653, 2001
21. Hotta K, Funahashi T, Arita Y, Takahashi M, Matsuda M, Okamoto Y, Iwahashi H, Kuriyama H, Ouchi N, Maeda K, Nishida K, Kihara S, Sakai N, Nakajima T, Hasegawa K, Muraguchi M, Ohmoto Y, Nakamura T, Yamashita S, Hanafusa T, Matsuzawa Y: Plasma concentrations of a novel, adipose-specific protein, adiponectin in type 2 diabetic patients. Arteriocler Thromb Vasc Biol 20:1595-1599, 2000
22. Arita K, Kihara S, Ouchi N, Takahashi M, Maeda K, Miyagawa J, Hotta K, Shimomura I, Nakamura T, Miyaoka K, Kuriyama H, Nishida M, Yamashita S, Okubo K, Matsubara K, Muraguchi M, Ohmoto Y, Funahashi T, Matzusawa Y: Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophy Res Commun 257:79-83, 1999
23. Weyer C, Funahashi T, Tanaka S, Hotta K, Matsuzawa Y, Pratley RE, Tataranni A: Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 86:1930-1935, 2001
24. Yamauchi T, Kamon J, Waki H, Terauchi Y, Kubota N, Hara K, Mori Y, Ide T, Murakami K, Tsuboyama-Kasaoka N, Ezaki O, Akanuma Y, Gavrilova O, Vinson C, Reitman ML, Kagechika H, Shudo K, Yoda M, Nakano Y, Tobe K, Nagai R, Kimura S, Tomita M, Froguel P, Kadowaki T: The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nature Med 7:941-946, 2001
25. Combs TP, Berg AH, Obici S, Scherer PE, Rosetti L: Endogenous glucose production is inhibited by the adipose-derived protein Acrp30. J Clin Invest 108:1875-1881, 2001
26. Desbuquois B, Auerbach GD: Use of polyethylene glycol to separate free and antibody bound peptide hormones in radioimmunoassays. J Clin Endocrinol Metab 33:732-738, 1971
27. Steele R: Influences of glucose loading and of injected insulin on hepatic glucose output. Ann N Y Acad Sci 82:420-430, 1959
28. Wolfe RR: Tracers in Metabolic Research: Radioisotope/Mass Spectrometry Methods. Alan R. Liss Inc., New York, 1984, p. 81-101
29. Maeda K, Okubo K, Shimomura I, Funahashi T, Matsuzawa Y, Matsubara K: cDNA cloning of a novel adipose-specific collagen-like factor, APM1 (adipose most abundant gene transcript 1). Biochem Biophys Res Commun 221:286-289, 1996
30. Shapiro L, Scherer P: The crystal structure of a complement-1q family protein suggests an evolutionary link to tumor necrosis factor. Curr Biol 12:335-338, 1996
31. Berg AH, Combs TP, Du X, Brownlee M, Scherer PE: The adipocyte-secreted protein Acrp30 enhances hepatic insulin action. Nature Med 7:947-953, 2001
32. Fruebis J, Tsao TS, Javorschi S, Ebbets-Reed D, Erickson MRS, Yen FT, Bihain BE, Lodish HF: Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice. Proc Natl Acad Sci U S A 98:2005-2010, 2001
33. Yokota T, Oritani K, Takahashi I, Ishikawa J, Matsuyama A, Ouchi N, Kihara S, Funahashi T, Tenner AJ, Tomiyama Y, Matsuzawa Y: Adiponectin, a new member of the family of soluble defense collagens, negatively regulates the growth of myelomonocytic progenitors and the functions of macrophages. Blood 96:1723-1732, 2000
34. Ouchi N, Kihara S, Arita Y, Maeda K, Kuriyama H, Okamoto Y, Hotta K, Nishida M, Takahashi M, Nakamura T, Yamashita S, Funahashi T, Matsuzawa Y: Novel modulator of endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin. Circulation 100:2473-2476, 1999
35. Ouchi N, Kihara S, Arita Y, Okamoto Y, Maeda K, Kuriyama H, Hotta K, Nishida M, Takahashi M, Muraguchi M, Ohmota Y, Nakamura T, Yamashita S, Funahashi T, Matsuzawa Y: Adiponectin, an adipocyte-derived plasma protein, inhibits endothelial NK-κB signaling through a camp-dependent pathway. Circulation 102:1296-1301, 2000
36. Yang WS, Lee WJ, Funahashi T, Tanaka S, Matsuzawa Y, Chao CL, Chen CL, Tai TY, Chuang LM: Weight reduction increases plasma levels of an adipocyte-derived anti-inflammatory protein, adiponectin. J Clin Endocrinol Metab 86:3815-3819, 2001
37. Maeda N, Takahashi M, Funahashi T, Kihara S, Nishizawa H, Kishida K, Nagaretani H, Matsuda M, Komuro R, Ouchi N, Kuriyama H, Hotta K, Nakamura T, Shimomura I, Matsuzawa Y: PPARγ ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes 50:2094-2099, 2001
38. Hirose H, Kawai T, Yamamoto Y, Taniyama M, Tomita M, Matsubara K, Okazaki Y, Ishii T, Oguma Y, Takei I, Saruta T: Effects of pioglitazone on metabolic parameters, body fat distribution and serum adiponectin levels in Japanese male patients with type 2 diabetes. Metabolism 51:314-317, 2002
39. Yang WS, Jeng CY, Wu TJ, Tanaka S, Funahashi T, Matsuzawa Y, Wang JP, Chen CL, Tai TY, Chuang LM: Synthetic peroxisome proliferator-activated receptor-γ agonist, rosiglitazone, increases plasma levels of adiponectin in type 2 diabetic patients. Diabetes Care 25:376-380, 2002
40. Combs TP, Wagner JA, Berger J, Doebber T, Wang WJ, Zhang BB, Tanen M, Berg AH, O'Rahilly S, Savage DB, Chatterjee K, Weiss S, Larson PJ, Gottesdiener KM, Gertz BJ, Charron MJ, Scherer PE, Moller DE: Induction of adipocyte complement-related protein of 30 kilodaltons by PPAR-γ agonists: a potential mechanism of insulin sensitization. Endocrinology 143:998-1007, 2002
41. Suter SL, Nolan JJ, Wallace P, Gumbiner B, Olefsky JM: Metabolic effects of new oral hypoglycemic agent CS-045 in NIDDM subjects. Diabetes Care 15:193-203, 1992
42. Frias JP, Yu JG, Kruszynska YT, Olefsky JM: Metabolic effects of troglitazone therapy in type 2 diabetic, obese and lean normal subjects. Diabetes Care 23:64-69, 2000
43. Iwamoto Y, Kosaka K, Kuzuya T, Akanuma Y, Shigeta Y, Kaneko T: Effects of troglitazone. Diabetes Care 19:151-156, 1996